Literature DB >> 18156607

Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis.

Petros C Karakousis1, Ernest P Williams, William R Bishai.   

Abstract

OBJECTIVES: Despite having potent activity against actively replicating Mycobacterium tuberculosis, isoniazid has very limited activity against dormant bacilli. In order to investigate the lack of bactericidal activity of this drug under conditions leading to mycobacterial dormancy, we studied the transcriptional pattern of M. tuberculosis in different physiological states following exposure to isoniazid.
METHODS: Global gene expression analysis was used to study M. tuberculosis treated with isoniazid in dormancy models of nutrient depletion and progressive hypoxia in vitro, as well as in an in vivo hollow fibre model of dormancy. Mycobacterial expression of the drug's putative transcriptional signature was investigated by RT-PCR in each dormancy model, and during the early and chronic phases of infection in the mouse aerosol model. Transcriptional responses were correlated with the bactericidal activity of isoniazid in the respective models.
RESULTS: A small group of genes directly relevant to the mechanism of action of isoniazid was confirmed to constitute a transcriptional signature of the drug, as differential regulation of these genes was abrogated in an isoniazid-resistant, katG-deficient M. tuberculosis strain following isoniazid exposure. Isoniazid-induced expression of this transcriptional signature was abolished in dormant bacilli which had acquired phenotypic tolerance to isoniazid, regardless of the specific conditions responsible for the induction of the dormancy phenotype. Quantitative RT-PCR revealed that expression of isoniazid-regulated genes (IRGs) is dramatically altered under conditions of nutrient depletion and progressive hypoxia in vitro. Although these IRGs are highly induced following drug exposure early in infection in the mouse hollow fibre and aerosol models, correlating with potent bactericidal activity of the drug, their expression levels are markedly diminished during late-stage infection in these two models, coinciding with the greatly reduced bactericidal activity of isoniazid against these organisms.
CONCLUSIONS: The reduced susceptibility of bacilli to the bactericidal drug isoniazid, as well as lack of expression of IRGs upon exposure to the drug, may be defining features of M. tuberculosis dormancy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18156607     DOI: 10.1093/jac/dkm485

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  45 in total

1.  Systems biology approaches to understanding mycobacterial survival mechanisms.

Authors:  Helena I M Boshoff; Desmond S Lun
Journal:  Drug Discov Today Dis Mech       Date:  2010

2.  Examining the basis of isoniazid tolerance in nonreplicating Mycobacterium tuberculosis using transcriptional profiling.

Authors:  Griselda Tudó; Ken Laing; Denis A Mitchison; Philip D Butcher; Simon J Waddell
Journal:  Future Med Chem       Date:  2010-08       Impact factor: 3.808

Review 3.  Genetic Approaches to Facilitate Antibacterial Drug Development.

Authors:  Dirk Schnappinger
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-13       Impact factor: 6.915

4.  In vitro and in vivo fitness costs associated with Mycobacterium tuberculosis RpoB mutation H526D.

Authors:  Dalin Rifat; Victoria L Campodónico; Jing Tao; James A Miller; Alpaslan Alp; Yufeng Yao; Petros C Karakousis
Journal:  Future Microbiol       Date:  2017-03-27       Impact factor: 3.165

5.  Altered protein expression patterns of Mycobacterium tuberculosis induced by ATB107.

Authors:  Hongbo Shen; Enzhuo Yang; Feifei Wang; Ruiliang Jin; Shengfeng Xu; Qiang Huang; Honghai Wang
Journal:  J Microbiol       Date:  2010-06-23       Impact factor: 3.422

6.  Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis.

Authors:  Nicholas D Walter; Gregory M Dolganov; Benjamin J Garcia; William Worodria; Alfred Andama; Emmanuel Musisi; Irene Ayakaka; Tran T Van; Martin I Voskuil; Bouke C de Jong; Rebecca M Davidson; Tasha E Fingerlin; Katerina Kechris; Claire Palmer; Payam Nahid; Charles L Daley; Mark Geraci; Laurence Huang; Adithya Cattamanchi; Michael Strong; Gary K Schoolnik; John Lucian Davis
Journal:  J Infect Dis       Date:  2015-03-11       Impact factor: 5.226

7.  Stringent Response Factors PPX1 and PPK2 Play an Important Role in Mycobacterium tuberculosis Metabolism, Biofilm Formation, and Sensitivity to Isoniazid In Vivo.

Authors:  Yu-Min Chuang; Noton K Dutta; Chien-Fu Hung; T-C Wu; Harvey Rubin; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

8.  Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.

Authors:  Zahoor Ahmad; Eric L Nuermberger; Rokeya Tasneen; Michael L Pinn; Kathy N Williams; Charles A Peloquin; Jacques H Grosset; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2010-01-31       Impact factor: 5.790

9.  Capillary electrophoresis-single strand conformation polymorphism for the detection of multiple mutations leading to tuberculosis drug resistance.

Authors:  Sowmya Krothapalli; Michael K May; Christa N Hestekin
Journal:  J Microbiol Methods       Date:  2012-08-03       Impact factor: 2.363

10.  Interpreting expression data with metabolic flux models: predicting Mycobacterium tuberculosis mycolic acid production.

Authors:  Caroline Colijn; Aaron Brandes; Jeremy Zucker; Desmond S Lun; Brian Weiner; Maha R Farhat; Tan-Yun Cheng; D Branch Moody; Megan Murray; James E Galagan
Journal:  PLoS Comput Biol       Date:  2009-08-28       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.